TIL Therapies & Solid Tumor Cell Immunotherapy Market
完整報告名稱與涵蓋範圍
TIL Therapies & Solid Tumor Cell Immunotherapy Market Size, Share & Trends Analysis Report, By Therapy Type (Tumor-Infiltrating Lymphocyte Therapies, TCR-T Cell Therapies, CAR-T and CAR-NK Therapies for Solid Tumors), By Indication (Melanoma, Non-Small Cell Lung Cancer, Cervical, Head and Neck and Other Solid Tumors, Sarcoma and Rare Tumors), By Manufacturing Model (Centralised Manufacturing, Point-of-Care and Automated Manufacturing), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The TIL therapies and solid tumor cell immunotherapy market covers adoptive cell therapies directed at solid tumors, including tumor-infiltrating lymphocyte products, T-cell receptor-engineered T cells and CAR-T or CAR-NK candidates designed for solid malignancies, together with the manufacturing and treatment-center infrastructure that delivers them. Cell therapies for hematologic cancers are excluded.
Regulatory approvals of the first TIL product for advanced melanoma and the first TCR-T therapy for synovial sarcoma established that engineered and expanded T cells can generate durable responses in solid tumors, moving the field from academic programs to commercial products. Growth now depends on expanding into lung, cervical and head and neck cancers, reducing the several-week manufacturing cycle, managing the toxicity of lymphodepletion and high-dose interleukin-2, and improving persistence through gene edits and cytokine engineering. Automated and point-of-care manufacturing, neoantigen selection and combination with checkpoint inhibitors are the main technical levers under evaluation.
The United States accounts for nearly all commercial activity, with Europe, Japan and China expanding trial networks and treatment centers. The competitive field combines commercial-stage TIL and TCR-T companies, next-generation engineered T-cell developers and large pharmaceutical groups with solid tumor cell therapy programs.
The InsightAce study supplies US$ forecasts for all therapy type, indication, manufacturing model and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global TIL Therapies & Solid Tumor Cell Immunotherapy Market Snapshot
Chapter 4. Global TIL Therapies & Solid Tumor Cell Immunotherapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Therapy Type Estimates & Trend Analysis
5.1. Therapy Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapy Type:
5.2.1. Tumor-Infiltrating Lymphocyte Therapies
5.2.2. TCR-T Cell Therapies
5.2.3. CAR-T and CAR-NK Therapies for Solid Tumors
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Melanoma
6.2.2. Non-Small Cell Lung Cancer
6.2.3. Cervical, Head and Neck and Other Solid Tumors
6.2.4. Sarcoma and Rare Tumors
Chapter 7. Market Segmentation 3: By Manufacturing Model Estimates & Trend Analysis
7.1. Manufacturing Model & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Manufacturing Model:
7.2.1. Centralised Manufacturing
7.2.2. Point-of-Care and Automated Manufacturing
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Authorized Treatment Centers
8.2.2. Academic Cancer Centers
Chapter 9. TIL Therapies & Solid Tumor Cell Immunotherapy Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Iovance Biotherapeutics, Inc.
11.2. Adaptimmune Therapeutics plc (US WorldMeds)
11.3. Instil Bio, Inc.
11.4. Achilles Therapeutics plc
11.5. Immatics N.V.
11.6. Obsidian Therapeutics, Inc.
11.7. Turnstone Biologics Corp.
11.8. Lyell Immunopharma, Inc.
11.9. Tmunity/Cabaletta Bio, Inc.
11.10. Bristol Myers Squibb
11.11. Takara Bio Inc.
11.12. Cellular Biomedicine Group Inc.
11.13. Nurix Therapeutics, Inc.
11.14. Autolus Therapeutics plc
11.15. Moderna, Inc. (Individualized Neoantigen Programs)
圖表清單 List of Tables & Figures
Table 1. Global TIL Therapies & Solid Tumor Cell Immunotherapy Market Revenue Forecast by Therapy Type, 2026-2035 (US$ Mn)
Figure 1. Global TIL Therapies & Solid Tumor Cell Immunotherapy Market Segmentation Overview
Table 2. Global TIL Therapies & Solid Tumor Cell Immunotherapy Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global TIL Therapies & Solid Tumor Cell Immunotherapy Market Share by Therapy Type, 2026 & 2035
Table 3. Global TIL Therapies & Solid Tumor Cell Immunotherapy Market Revenue Forecast by Manufacturing Model, 2026-2035 (US$ Mn)
Figure 3. Solid Tumor Cell Therapy Pipeline by Modality, Indication and Phase, 2026
Table 4. Global TIL Therapies & Solid Tumor Cell Immunotherapy Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Global TIL Therapies & Solid Tumor Cell Immunotherapy Market Share by Indication, 2026 & 2035
Table 5. North America TIL Therapies & Solid Tumor Cell Immunotherapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Manufacturing Cycle Time and Cost Reduction Pathways for TIL Products
Table 6. Europe TIL Therapies & Solid Tumor Cell Immunotherapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific TIL Therapies & Solid Tumor Cell Immunotherapy Growth Opportunity Analysis
Table 7. Asia Pacific TIL Therapies & Solid Tumor Cell Immunotherapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Authorized Treatment Center Network Expansion by Region
Table 8. Latin America TIL Therapies & Solid Tumor Cell Immunotherapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key TIL Therapies & Solid Tumor Cell Immunotherapy Market Participants
Table 9. Middle East & Africa TIL Therapies & Solid Tumor Cell Immunotherapy Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們